Vascular effects of obestatin in lean and obese subjects

Diabetes

Volumn 66, Issue 5, 2017, Pages 1214-1221

  Schinzari, Francesca ^a   Veneziani, Augusto ^b   Mores, Nadia ^a   Barini, Angela ^a   Di Daniele, Nicola ^c   Cardillo, Carmine ^a   Tesauro, Manfredi ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; GHRELIN; N(G) METHYLARGININE; NITRIC OXIDE; OBESTATIN; SODIUM CHLORIDE; CYCLO(TRP-ASP-PRO-VAL-LEU); CYCLOPEPTIDE; ENDOTHELIN A RECEPTOR ANTAGONIST; ENZYME INHIBITOR;

ADULT; ARTICLE; BLOOD FLOW; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG INFUSION; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; FOREARM; HUMAN; LEAN BODY WEIGHT; MALE; OBESITY; PRIORITY JOURNAL; TREATMENT RESPONSE; VASOCONSTRICTION; VASODILATATION; ABDOMINAL OBESITY; CASE CONTROL STUDY; DRUG EFFECTS; METABOLISM; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ADULT; CASE-CONTROL STUDIES; ENDOTHELIN A RECEPTOR ANTAGONISTS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; FOREARM; GHRELIN; HUMANS; MALE; NITRIC OXIDE; OBESITY, ABDOMINAL; OMEGA-N-METHYLARGININE; PEPTIDES, CYCLIC; REGIONAL BLOOD FLOW; VASOCONSTRICTION; VASODILATION;

EID: 85019378259     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-1067     Document Type: Article

References (34)

1. Schinzari F, Tesauro M, Rovella V, et al. Generalized impairment of vasodilator reactivity during hyperinsulinemia in patients with obesity-related metabolic syndrome. Am J Physiol Endocrinol Metab 2010;299:E947-E952
2. Weil BR, Westby CM, Van Guilder GP, Greiner JJ, Stauffer BL, DeSouza CA. Enhanced endothelin-1 system activity with overweight and obesity. Am J Physiol Heart Circ Physiol 2011;301:H689-H695
3. Schinzari F, Iantorno M, Campia U, et al. Vasodilator responses and endothelin-dependent vasoconstriction in metabolically healthy obesity and the metabolic syndrome. Am J Physiol Endocrinol Metab 2015;309:E787-E792
4. Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005;310:996-999
5. Trovato L, Gallo D, Settanni F, Gesmundo I, Ghigo E, Granata R. Obestatin: is it really doing something? Front Horm Res 2014;42:175-185
6. Granata R, Settanni F, Gallo D, et al. Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. Diabetes 2008;57:967-979
7. Cowan E, Burch KJ, Green BD, Grieve DJ. Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes. Br J Pharmacol 2016;173:2165-2181
8. Granata R, Gallo D, Luque RM, et al. Obestatin regulates adipocyte function and protects against diet-induced insulin resistance and inflammation. FASEB J 2012;26:3393-3411
9. Agnew AJ, Robinson E, McVicar CM, et al. The gastrointestinal peptide obestatin induces vascular relaxation via specific activation of endotheliumdependent NO signalling. Br J Pharmacol 2012;166:327-338
10. Ku JM, Andrews ZB, Barsby T, et al. Ghrelin-related peptides exert protective effects in the cerebral circulation of male mice through a nonclassical ghrelin receptor (s). Endocrinology 2015;156:280-290
11. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-438
12. Tostes RC, Fortes ZB, Callera GE, et al. Endothelin, sex and hypertension. Clin Sci (Lond) 2008;114:85-97
13. Tesauro M, Schinzari F, Rovella V, et al. Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. Hypertension 2009;54:995-1000
14. Schinzari F, Tesauro M, Rovella V, et al. Leptin stimulates both endothelin-1 and nitric oxide activity in lean subjects but not in patients with obesity-related metabolic syndrome. J Clin Endocrinol Metab 2013;98:1235-1241
15. Wilkinson IB, Webb DJ. Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br J Clin Pharmacol 2001;52:631-646
16. Anderwald-Stadler M, Krebs M, Promintzer M, et al. Plasma obestatin is lower at fasting and not suppressed by insulin in insulin-resistant humans. Am J Physiol Endocrinol Metab 2007;293:E1393-E1398
17. Li ZF, Guo ZF, Yang SG, Zheng X, Cao J, Qin YW. Circulating ghrelin and ghrelin to obestatin ratio are low in patients with untreated mild-to-moderate hypertension. Regul Pept 2010;165:206-209
18. Wang WM, Li SM, Du FM, Zhu ZC, Zhang JC, Li YX. Ghrelin and obestatin levels in hypertensive obese patients. J Int Med Res 2014;42:1202-1208
19. Tesauro M, Schinzari F, Iantorno M, et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 2005;112:2986-2992
20. Virdis A, Duranti E, Colucci R, et al. Ghrelin restores nitric oxide availability in resistance circulation of essential hypertensive patients: role of NAD (P) H oxidase. Eur Heart J 2015;36:3023-3030
21. Mao Y, Tokudome T, Kishimoto I. Ghrelin as a treatment for cardiovascular diseases. Hypertension 2014;64:450-454
22. Nagaraj S, Peddha MS, Manjappara UV. Fragments of obestatin as modulators of feed intake, circulating lipids, and stored fat. Biochem Biophys Res Commun 2008;366:731-737
23. Flowers MA, Wang Y, Stewart RJ, Patel B, Marsden PA. Reciprocal regulation of endothelin-1 and endothelial constitutive NOS in proliferating endothelial cells. Am J Physiol 1995;269:H1988-H1997
24. Guo ZF, Zheng X, Qin YW, Hu JQ, Chen SP, Zhang Z. Circulating preprandial ghrelin to obestatin ratio is increased in human obesity. J Clin Endocrinol Metab 2007;92:1875-1880
25. Gu PY, Kang DM, Wang WD, Chen Y, Zhao ZH, Zheng H, Ye SD. Relevance of plasma obestatin and early arteriosclerosis in patients with type 2 diabetes mellitus. J Diabetes Res 2013;2013:563919
26. Haider DG, Schindler K, Prager G, et al. Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab 2007;92:1168-1171
27. Lee WJ, Chen CY, Ser KH, et al. Differential influences of gastric bypass and sleeve gastrectomy on plasma nesfatin-1 and obestatin levels in patients with type 2 diabetes mellitus. Curr Pharm Des 2013;19:5830-5835
28. Vicennati V, Genghini S, De Iasio R, Pasqui F, Pagotto U, Pasquali R. Circulating obestatin levels and the ghrelin/obestatin ratio in obese women. Eur J Endocrinol 2007;157:295-301
29. Mora M, Granada ML, Roca M, et al. Obestatin does not modify weight and nutritional behaviour but is associated with metabolic syndrome in old women. Clin Endocrinol (Oxf) 2013;78:882-890
30. Roth CL, Reinehr T, Schernthaner GH, Kopp HP, Kriwanek S, Schernthaner G. Ghrelin and obestatin levels in severely obese women before and after weight loss after Roux-en-Y gastric bypass surgery. Obes Surg 2009;19:29-35
31. Siejka A, Jankiewicz-Wika J, Kołomecki K, et al. Long-term impact of vertical banded gastroplasty (VBG) on plasma concentration of leptin, soluble leptin receptor, ghrelin, omentin-1, obestatin, and retinol binding protein 4 (RBP4) in patients with severe obesity. Cytokine 2013;64:490-493
32. Seim I, Walpole C, Amorim L, Josh P, Herington A, Chopin L. The expanding roles of the ghrelin-gene derived peptide obestatin in health and disease. Mol Cell Endocrinol 2011;340:111-117
33. Ingelfinger JR, Rosen CJ. Cardiac and renovascular complications in type 2 diabetes-is there hope? N Engl J Med 2016;375:380-382
34. Vergote V, Van Dorpe S, Peremans K, Burvenich C, De Spiegeleer B. In vitro metabolic stability of obestatin: kinetics and identification of cleavage products. Peptides 2008;29:1740-1748